Equities

Tsumura & Co

Tsumura & Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,950.00
  • Today's Change54.00 / 1.39%
  • Shares traded142.60k
  • 1 Year change+41.93%
  • Beta0.7029
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.

  • Revenue in JPY (TTM)157.50bn
  • Net income in JPY23.56bn
  • Incorporated1936
  • Employees4.14k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Towa Pharmaceutical Co Ltd235.95bn16.92bn152.38bn4.59k8.610.89334.320.6458343.72343.724,793.823,311.490.55821.493.6051,428,070.004.004.214.915.6335.9039.237.177.231.62--0.566621.019.1316.74634.803.7228.2010.86
Kissei Pharmaceutical Co Ltd77.43bn12.00bn172.10bn1.78k13.000.701910.482.22268.51268.511,728.184,972.530.32041.552.9043,524,450.005.003.615.383.9049.9049.4715.5912.694.93--0.00634.8711.980.89196.0015.286.5810.40
KAKEN PHARMACEUTICAL CO., LTD.72.15bn7.27bn179.85bn1.14k20.381.0417.922.49192.09192.091,906.843,763.430.4221.983.2363,566,520.004.256.834.887.8753.4154.7810.0814.483.98--0.026351.25-1.29-5.2147.52-14.700.36390.00
Sumitomo Pharma Co Ltd329.55bn-260.17bn229.59bn4.98k--1.43--0.6967-654.85-654.85829.49404.890.3281.203.8866,174,100.00-25.89-5.07-45.34-7.7360.2269.99-78.94-12.280.419--0.7079---43.38-7.29-322.71--4.02--
Nippon Shinyaku Co., Ltd.150.37bn27.37bn235.41bn2.21k8.250.99367.221.57406.30406.302,232.623,372.500.59761.373.2067,949,390.0010.8810.4512.4112.3166.8161.2718.2016.473.73--0.011432.622.835.2613.329.6645.9312.12
Sawai Group Holdings Co Ltd178.04bn17.78bn266.44bn3.48k15.011.258.821.50404.94584.994,058.784,883.080.46711.172.8351,130,670.003.480.71044.620.970531.1435.087.441.471.5843.190.292788.138.04-0.824946.82-2.3318.150.00
Tsumura & Co157.50bn23.56bn299.05bn4.14k12.561.058.291.90310.18310.182,073.963,712.370.37030.70432.2938,061,620.005.904.817.395.8947.5950.9815.9412.652.31--0.205832.167.714.521.372.7417.545.84
Hisamitsu Pharmaceutical Co Inc145.42bn14.71bn332.99bn2.76k20.291.0816.122.29192.71192.711,905.693,607.430.44133.013.6152,707,500.004.624.225.504.8255.7458.6210.4710.033.09--0.004253.0510.42-0.238518.97-6.1728.900.5989
Data as of Sep 19 2024. Currency figures normalised to Tsumura & Co's reporting currency: Japanese Yen JPY

Institutional shareholders

27.39%Per cent of shares held by top holders
HolderShares% Held
Marathon Asset Management Ltd.as of 29 Mar 20245.59m7.29%
Invesco Asset Management (Japan) Ltd.as of 15 Aug 20243.38m4.40%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Apr 20242.52m3.29%
The Vanguard Group, Inc.as of 04 Sep 20242.26m2.94%
Nomura Asset Management Co., Ltd.as of 30 Aug 20241.93m2.51%
Templeton Investment Counsel LLCas of 31 Jul 20241.23m1.60%
Norges Bank Investment Managementas of 31 Dec 20231.20m1.57%
Baillie Gifford & Co.as of 31 Aug 2024999.30k1.30%
Dimensional Fund Advisors LPas of 05 Sep 2024971.85k1.27%
Nikko Asset Management Co., Ltd.as of 15 Apr 2024938.80k1.22%
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.